OBJECTIVE: To identify racial and ethnic differences in mortality and cardiovascular (CV) risk among patients with end-stage renal disease (ESRD) due to lupus nephritis (LN). METHODS: Within the US ESRD registry (1995-2008), we identified individuals ages >17 years with incident ESRD due to systemic lupus erythematosus. We ascertained demographics, clinical factors, and deaths from registry patient files and CV events (myocardial infarction, heart failure, and hemorrhagic and ischemic strokes) from inpatient Medicare claims. We calculated incidence rates (95% confidence intervals [95% CIs]) per 1,000 person-years for study events, stratified by race and ethnicity. We compared probabilities of the events among racial and ethnic groups using cumulative incidence function curves and multivariable-adjusted subdistribution proportional hazard ratios (HRsd), taking into account the competing events of kidney transplantation and death (for nonfatal CV events). RESULTS: Of 12,533 patients with LN-associated ESRD, the mean ± SD age was 40.7 ± 14.9 years, 82% were women, and 49% were African American. The overall mortality rate was 98.1/1,000 person-years (95% CI 95.3-100.9). In multivariable models, Asian and Hispanic LN-associated ESRD patients had lower mortality than whites (HRsd 0.70 [95% CI 0.58-0.84] and 0.79 [95% CI 0.71-0.88], respectively), whereas African Americans had higher mortality (HRsd 1.27 [95% CI 1.18-1.36]). African American patients >40 years old had higher mortality than their white counterparts (HRsd 1.67 [95% CI 1.44-1.93]). African Americans were more likely to be admitted for heart failure or hemorrhagic stroke. CONCLUSION: Among patients with LN-associated ESRD, Asians and Hispanics experienced lower mortality and CV event risks than whites, and African Americans had higher mortality and CV event risks than whites.
OBJECTIVE: To identify racial and ethnic differences in mortality and cardiovascular (CV) risk among patients with end-stage renal disease (ESRD) due to lupus nephritis (LN). METHODS: Within the US ESRD registry (1995-2008), we identified individuals ages >17 years with incident ESRD due to systemic lupus erythematosus. We ascertained demographics, clinical factors, and deaths from registry patient files and CV events (myocardial infarction, heart failure, and hemorrhagic and ischemic strokes) from inpatient Medicare claims. We calculated incidence rates (95% confidence intervals [95% CIs]) per 1,000 person-years for study events, stratified by race and ethnicity. We compared probabilities of the events among racial and ethnic groups using cumulative incidence function curves and multivariable-adjusted subdistribution proportional hazard ratios (HRsd), taking into account the competing events of kidney transplantation and death (for nonfatal CV events). RESULTS: Of 12,533 patients with LN-associated ESRD, the mean ± SD age was 40.7 ± 14.9 years, 82% were women, and 49% were African American. The overall mortality rate was 98.1/1,000 person-years (95% CI 95.3-100.9). In multivariable models, Asian and Hispanic LN-associated ESRDpatients had lower mortality than whites (HRsd 0.70 [95% CI 0.58-0.84] and 0.79 [95% CI 0.71-0.88], respectively), whereas African Americans had higher mortality (HRsd 1.27 [95% CI 1.18-1.36]). African American patients >40 years old had higher mortality than their white counterparts (HRsd 1.67 [95% CI 1.44-1.93]). African Americans were more likely to be admitted for heart failure or hemorrhagic stroke. CONCLUSION: Among patients with LN-associated ESRD, Asians and Hispanics experienced lower mortality and CV event risks than whites, and African Americans had higher mortality and CV event risks than whites.
Authors: J Bradley Layton; Susan L Hogan; Caroline E Jennette; Barbara Kenderes; Jenna Krisher; J Charles Jennette; William M McClellan Journal: Clin J Am Soc Nephrol Date: 2010-08-05 Impact factor: 8.237
Authors: H M Bastian; J M Roseman; G McGwin; G S Alarcón; A W Friedman; B J Fessler; B A Baethge; J D Reveille Journal: Lupus Date: 2002 Impact factor: 2.911
Authors: Antoni Sisó; Manuel Ramos-Casals; Albert Bové; Pilar Brito-Zerón; Natalia Soria; Norma Nardi; Adriana Testi; Marta Perez-de-Lis; Cándido Díaz-Lagares; Alejandro Darnell; Juan Sentís; Antonio Coca Journal: Medicine (Baltimore) Date: 2010-09 Impact factor: 1.889
Authors: Ricard Cervera; Munther A Khamashta; Josep Font; Gian Domenico Sebastiani; Antonio Gil; Paz Lavilla; Juan Carlos Mejía; A Olcay Aydintug; Hanna Chwalinska-Sadowska; Enrique de Ramón; Antonio Fernández-Nebro; Mauro Galeazzi; Merete Valen; Alessandro Mathieu; Frédéric Houssiau; Natividad Caro; Paula Alba; Manuel Ramos-Casals; Miguel Ingelmo; Graham R V Hughes Journal: Medicine (Baltimore) Date: 2003-09 Impact factor: 1.889
Authors: Medha Barbhaiya; Candace H Feldman; Hongshu Guan; Jose A Gómez-Puerta; Michael A Fischer; Daniel H Solomon; Brendan Everett; Karen H Costenbader Journal: Arthritis Rheumatol Date: 2017-08-13 Impact factor: 10.995
Authors: Medha Barbhaiya; Candace H Feldman; Hongshu Guan; Sarah K Chen; Michael A Fischer; Daniel H Solomon; Brendan M Everett; Karen H Costenbader Journal: Semin Arthritis Rheum Date: 2018-07-31 Impact factor: 5.532
Authors: Candace H Feldman; Cameron Speyer; Rachel Ashby; Bonnie L Bermas; Shamik Bhattacharyya; Eliza Chakravarty; Brendan Everett; Elizabeth Ferucci; Aimee O Hersh; Francisco M Marty; Joseph F Merola; Rosalind Ramsey-Goldman; Brad H Rovin; Mary Beth Son; Laura Tarter; Sushrut Waikar; Jinoos Yazdany; Joel S Weissman; Karen H Costenbader Journal: Arthritis Care Res (Hoboken) Date: 2021-01 Impact factor: 4.794
Authors: May Y Choi; Daniel Li; Candace H Feldman; Kazuki Yoshida; Hongshu Guan; Seoyoung C Kim; Brendan M Everett; Karen H Costenbader Journal: Rheumatology (Oxford) Date: 2021-08-02 Impact factor: 7.580